Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

BACKGROUND: Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in better outcomes in patients with severe Covid-19 p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Rosas, Ivan O., Bräu, Norbert, Waters, Michael, Go, Ronaldo C., Hunter, Bradley D., Bhagani, Sanjay, Skiest, Daniel, Aziz, Mariam S., Cooper, Nichola, Douglas, Ivor S., Savic, Sinisa, Youngstein, Taryn, Del Sorbo, Lorenzo, Cubillo Gracian, Antonio, De La Zerda, David J., Ustianowski, Andrew, Bao, Min, Dimonaco, Sophie, Graham, Emily, Matharu, Balpreet, Spotswood, Helen, Tsai, Larry, Malhotra, Atul
Formato: Artigo
Idioma:Inglês
Publicado em: Massachusetts Medical Society 2021
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7953459/
https://ncbi.nlm.nih.gov/pubmed/33631066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2028700
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados